MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Lyra Therapeutics ROA Ratio 2011-2026 | LYRA
Annual ROA Ratio Lyra Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -43.96 | -50.27 | -79.31 | -27.37 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -27.37 | -79.31 | -50.23 |
Quarterly ROA Ratio Lyra Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -58.09 | -59.47 | -96.22 | -81.83 | -94.81 | -92.71 | -54.25 | -42.72 | -55.08 | -54.46 | -53.09 | -48.57 | -64.88 | -68.83 | -72.25 | -41.48 | -49.31 | -40.83 | -31.99 | -18.69 | -46.51 | -66.5 | -88.96 | -79.88 | -79.88 | -52.06 | -23.99 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -18.69 | -96.22 | -59.9 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-10.79 | $ 3.55 | -0.42 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
-27.92 | $ 3.25 | 3.83 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-101.11 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptorum Group Limited
APM
|
-26.46 | $ 0.79 | 0.04 % | $ 4.31 M | China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-37.22 | $ 4.12 | -1.9 % | $ 105 M | Schweiz |
 |
Arcturus Therapeutics Holdings
ARCT
|
-24.26 | $ 6.52 | -1.66 % | $ 179 M |  Israel |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
argenx SE
ARGX
|
-14.32 | $ 709.0 | 0.81 % | $ 25 B |  Niderland |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 229.5 | -0.66 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.43 | -4.99 % | $ 8.25 B |  Australia |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-50.23 | $ 6.08 | 0.41 % | $ 495 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
-144.48 | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
-49.57 | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-30.55 | $ 14.54 | 1.25 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
BioCardia
BCDA
|
-387.38 | $ 1.3 | 2.36 % | $ 27.5 M | USA |
 |
Aptose Biosciences
APTO
|
-251.11 | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
-50.64 | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-10.92 | $ 2.59 | -1.79 % | $ 16.3 M | USA |
 |
Avenue Therapeutics
ATXI
|
-437.72 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-28.19 | $ 1.51 | -0.33 % | $ 385 M | Britain |
 |
Athira Pharma
ATHA
|
-164.92 | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 94.8 | 4.71 % | $ 27.2 B | Germany |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Burford Capital Limited
BUR
|
5.51 | $ 8.29 | 2.79 % | $ 1.34 B | Britain |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | Britain |
 |
Actinium Pharmaceuticals
ATNM
|
-49.73 | $ 1.15 | 3.6 % | $ 34.6 M | USA |